Fitbit in Alliance With Bristol-Myers Squibb-Pfizer to Help Reduce Stroke Risk

Fitbit is working with the Bristol-Myers Squibb-Pfizer Alliance to help drive timely diagnosis of atrial fibrillation for individuals at increased risk of stroke, they said Thursday. Upon Food and Drug Administration clearance of the detection software on Fitbit devices, the parties hope to give users information they can use in discussions with physicians, they said. With 24/7 on-wrist health tracking and associated software, Fitbit believes it can help “bridge the gaps that exist in atrial fibrillation detection, encouraging people to visit their doctor for a prompt diagnosis and potentially reduce their risk of stroke,” said CEO James Park.